Glanbia Q1 2026 results show real momentum – and the full-year outlook just got better
Glanbia has started 2026 strongly. The headline number is like-for-like revenue growth of 7.2% in the first quarter, with all three divisions growing volumes, and management now expects full-year adjusted earnings per share (EPS) to land at the upper end of its 7% to 11% constant currency guidance range.
That matters because upgrades are what investors want to see. A company can talk all day about “momentum”, but when it actually nudges expectations higher after Q1, that is a much more useful signal. On the face of it, this is a good update.
Key Glanbia Q1 2026 numbers retail investors should know
| Metric | Q1 2026 |
|---|---|
| Group like-for-like revenue growth | 7.2% |
| Group volume growth | 8.2% |
| Group price movement | (1.0%) |
| Total constant currency revenue growth | 3.8% |
| Total reported revenue growth | 5.4% |
| Performance Nutrition like-for-like growth | 11.5% |
| Health & Nutrition like-for-like growth | 11.6% |
| Dairy Nutrition like-for-like growth | 2.0% |
| Share buybacks year-to-date | €22.2 million |
| Net debt at 4 April 2026 | $648 million |
A quick bit of jargon. Like-for-like means stripping out the effect of acquisitions and disposals so you get a cleaner read on the underlying business. Constant currency means exchange rate movements are removed, which matters for a global group like Glanbia.
Why Glanbia’s Q1 growth looks better than the headline might first suggest
The most encouraging thing in this update is that growth was volume-led. Group volumes rose 8.2%, while pricing fell 1.0%. In plain English, Glanbia sold more stuff, and that is usually a healthier sign than relying purely on price increases.
That is especially true in consumer and nutrition markets, where price-led growth can run out of road if shoppers push back. Volume growth across all three segments suggests demand is holding up well.
There is also a decent quality to the growth mix. Performance Nutrition and Health & Nutrition both delivered double-digit like-for-like revenue growth, while Dairy Nutrition still managed to stay positive despite weaker pricing in cheese markets.
Performance Nutrition led by Optimum Nutrition is doing the heavy lifting
Performance Nutrition was the standout again, with like-for-like revenue up 11.5%. Volumes rose 9.2% and price added another 2.3%.
That growth was driven by strong category demand, new distribution, innovation, and an easier comparative period. The company also said pricing benefited from increases pushed through in the Americas in the fourth quarter last year, although that was partly offset by promotions and tactical price reductions in energy products.
Optimum Nutrition remains the star brand
Optimum Nutrition, which made up 78% of Performance Nutrition revenue, posted like-for-like growth of 18.8%. That is a big number for a brand of this scale, and it shows the core engine is still firing.
US consumption growth for Optimum Nutrition was 13.3% over the last 13 weeks. That is useful because it points to genuine consumer demand, not just stock being pushed into the channel.
International growth was far stronger than the Americas
There was a clear split by geography. PN Americas, representing 57% of segment revenue, grew 4.0% like-for-like. PN International, which represented 43%, grew a hefty 23.4%.
That tells you two things. First, international markets are currently providing the bigger growth kicker. Second, the Americas business is still growing, but at a more moderate pace, with Optimum Nutrition and Isopure gains partly offset by declines in other brands.
One slight drag here is that total constant currency growth for Performance Nutrition was only 1.3%, despite like-for-like growth of 11.5%, because acquisitions and disposals knocked off 10.2%. The reason for that hit is not disclosed in this RNS.
Health & Nutrition growth adds balance and looks commercially solid
Health & Nutrition delivered like-for-like revenue growth of 11.6%, with volumes up 12.5% and prices down 0.9%. Again, the really attractive part is the volume growth.
The price decline does not look alarming from what Glanbia says. It was due to pass-through pricing with customers, which usually means the business is adjusting prices in line with input costs rather than sacrificing margin for the sake of growth.
The segment also got a 3.2% boost from acquisitions, namely Sweetmix and Scicore. Glanbia said it is making good progress on capacity expansions in the US, China and Europe, which suggests management still sees a decent runway for demand in Active Nutrition, Functional Beverages, and Vitamins, Minerals & Supplements.
Dairy Nutrition growth is modest but better than it sounds
Dairy Nutrition will not grab the headlines, but this was a respectable quarter. Like-for-like revenue rose 2.0%, driven by 6.4% volume growth, partly offset by a 4.4% fall in price.
The weak pricing came from negative cheese markets in the first quarter. That is the bad news. The better news is that demand for high-end whey proteins was strong, with double-digit volume growth in protein solutions, and whey protein pricing was also in double digits.
So while Dairy Nutrition remains the least exciting part of the group, it is not falling over. Glanbia now expects DN EBITDA to be in the range of $160 million to $170 million for 2026, which is helpful. The previous exact guidance range is not disclosed in this announcement.
Share buybacks and debt – supportive, but not the main story
Glanbia bought back and cancelled 1,296,487 ordinary shares between 25 February 2026 and 27 April 2026. That returned €22.2 million to shareholders at an average price of €17.14 per share.
Buybacks can support earnings per share by reducing the share count, and they also signal management confidence. It is a positive, although in this case the bigger driver of investor interest is the improved trading outlook rather than the buyback itself.
On the balance sheet, net debt stood at $648 million at 4 April 2026, up $69 million versus the end of Q1 2025. That is higher, but it does not look uncomfortable given the group still had $1.4 billion of committed debt facilities. Management described the balance sheet as remaining in a strong position.
What Glanbia’s upgraded 2026 EPS guidance means for investors
The key line in this RNS is simple: Glanbia now expects full-year 2026 adjusted EPS growth at the upper end of its 7% to 11% constant currency guidance range. That is not a formal number, but it points investors towards something closer to 11% than 7% if current trading holds up.
That is a meaningful upgrade in tone after only one quarter. It suggests management has seen enough in the order book, demand backdrop, and category trends to become more confident.
It also said Performance Nutrition and Health & Nutrition revenues are now expected to be at the upper end of their medium-term guidance ranges. The exact ranges are not disclosed in this RNS, so investors will need prior company materials for the full detail.
My take on the Glanbia Q1 update – more good than bad
This reads as a positive statement. The best part is not just that Glanbia grew, but how it grew: strong volumes, broad-based segment performance, and a clear upgrade to full-year EPS expectations.
The negatives are relatively modest. Performance Nutrition still has some weaker brands outside its winners, Dairy Nutrition pricing remains exposed to softer cheese markets, and management is still flagging geopolitical uncertainty. None of that disappears.
But taken together, this looks like a business with healthy demand, strong flagship brands, and decent operational momentum. For retail investors, the main message is that Glanbia is trading better than expected, and management has become more confident early in the year. That is usually the kind of update the market likes.
